Format

Send to

Choose Destination
Tumori. 2019 Dec;105(6):488-493. doi: 10.1177/0300891619869505. Epub 2019 Sep 9.

Neoadjuvant therapy for breast cancer.

Author information

1
Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy.
2
Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3
RTR Liguria, IRCCS AOU SM-IST, Liguria, Italy.
4
Department of Public Health, Local Health Unit, Modena, Italy.
5
Latina Cancer Registry, Lazio, Italy.
6
Department of Health Promotion and of Maternal and Childhood Sciences, University of Palermo, Palermo, Italy.
7
Histopathology Department and Cancer Registry, Provincial Health Authority, ASP Ragusa, Ragusa, Italy.

Abstract

OBJECTIVE:

To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I-III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area.

METHODS:

Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009-2013). Included were 3546 women aged <85 years (groups <50, 50-69, 70-64, and 75+) with stage I-III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic models were built to test the association with biological and contextual variables.

RESULTS:

Only 8.2% of women (290 cases) underwent NT; the treatment decreases with increasing age (14.5% in age <50 and 2.2% in age 75+), is more frequent in women with negative receptors (14.8%), HER2-positive (15.7%), and triple-negative (15.6%). The multivariable analysis showed the probability of receiving NT is higher in stage III (odds ratio [OR] 3.83; 95% confidence interval [CI] 2.83-5.18), luminal B (OR 1.87; 95% CI 1.27-2.76), triple-negatives (OR 1.88; 95% CI 1.15-3.08), and in symptomatic cancers (OR 1.98; 95% CI 1.13-3.48). Use of NT varied among geographic areas: Reggio Emilia had the highest rates (OR 2.29; 95% CI 1.37-3.82) while Palermo had the lowest (OR 0.41; 95% CI 0.24-0.68).

CONCLUSIONS:

The use of NT in Italy is limited and variable. There are no signs of greater use in hospitals with more advanced care.

KEYWORDS:

Breast cancer; multidisciplinary; neoadjuvant therapy

PMID:
31496430
DOI:
10.1177/0300891619869505
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center